Kanagala_et_al-2018-Journal_of_Cardiovascular_Magnetic_Resonance.pdf (1.14 MB)
Download file

Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in heart failure with preserved ejection fraction - implications for clinical trials.

Download (1.14 MB)
journal contribution
posted on 26.01.2018, 15:38 by Prathap Kanagala, Adrian S. H. Cheng, Anvesha Singh, John McAdam, Anna-Marie Marsh, Jayanth R. Arnold, Iain B. Squire, Leong L. Ng, Gerry P. McCann
BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a poorly characterized condition. We aimed to phenotype patients with HFpEF using multiparametric stress cardiovascular magnetic resonance imaging (CMR) and to assess the relationship to clinical outcomes. METHODS: One hundred and fifty four patients (51% male, mean age 72 ± 10 years) with a diagnosis of HFpEF underwent transthoracic echocardiography and CMR during a single study visit. The CMR protocol comprised cine, stress/rest perfusion and late gadolinium enhancement imaging on a 3T scanner. Follow-up outcome data (death and heart failure hospitalization) were captured after a minimum of 6 months. RESULTS: CMR detected previously undiagnosed pathology in 42 patients (27%), who had similar baseline characteristics to those without a new diagnosis. These diagnoses consisted of: coronary artery disease (n = 20, including 14 with 'silent' infarction), microvascular dysfunction (n = 11), probable or definite hypertrophic cardiomyopathy (n = 10) and constrictive pericarditis (n = 5). Four patients had dual pathology. During follow-up (median 623 days), patients with a new CMR diagnosis were at higher risk of adverse outcome for the composite endpoint (log rank test: p = 0.047). In multivariate Cox proportional hazards analysis, a new CMR diagnosis was the strongest independent predictor of adverse outcome (hazard ratio: 1.92; 95% CI: 1.07 to 3.45; p = 0.03). CONCLUSIONS: CMR diagnosed new significant pathology in 27% of patients with HFpEF. These patients were at increased risk of death and heart failure hospitalization. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03050593 . Retrospectively registered; Date of registration: February 06, 2017.

Funding

This work was supported by and falls under the portfolio of research conducted within the National Institute for Health Research (NIHR) Leicester Cardiovascular Biomedical Research Unit. Overall project Grant: IRS IS_BRU_0211_20033.

History

Citation

Journal of Cardiovascular Magnetic Resonance, 2018, 20:4

Author affiliation

/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Department of Cardiovascular Sciences

Version

VoR (Version of Record)

Published in

Journal of Cardiovascular Magnetic Resonance

Publisher

BioMed Central for Society for Cardiovascular Magnetic Resonance

issn

1097-6647

eissn

1532-429X

Acceptance date

14/12/2017

Copyright date

2018

Available date

26/01/2018

Publisher version

https://jcmr-online.biomedcentral.com/articles/10.1186/s12968-017-0424-9

Notes

The datasets generated during and/or analysed during the current study are available from the corresponding author (GPM) upon reasonable request.

Language

en